Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation...
Vous n'êtes pas connecté
Zegalogue (dasiglucagon, Zealand Pharma) has been recommended by the European Medicines Agency (EMA) for the treatment of severe hypoglycemia in patients aged six years and older with diabetes. Severe hypoglycemia is defined as having low blood glucose levels that requires assistance from another person to treat. However, the active substance of Zegalogue is dasiglucagon, a […]
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation...
An innovative algorithm enhances blood sugar management, reducing severe hyperglycemia and hypoglycemia in hospitalized patients.
A new study from the Karolinska Institutet, published in the journal eClinicalMedicine, reveals that GLP-1 agonists, a type of medication used to...
A recent study by the FDA, published in the Annals of Internal Medicine, has highlighted a significant health concern linked to a modern class of...
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin,...
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin,...
Diabetes is a common health condition where the body either can’t produce enough insulin or can’t use insulin effectively, leading to high levels...
A healthy diet that adheres to nutrition recommendations is associated with better blood glucose levels and a lower risk of prediabetes and type 2...
June 24, 2024 -- The U.S. Food and Drug Administration (FDA) has approved PiaSky (crovalimab-akkz) for the treatment of adult and pediatric patients...
People with type 2 diabetes who are treated with GLP-1 agonists have a decreased risk of developing dementia, according to a new study from...